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Despite our best efforts to vaccinate against influenza viruses they remain a major cause of morbidity and 
mortality worldwide, resulting in 3-5 million severe infections and more than 250,000 deaths annually. Constant 
antigenic changes in circulating viruses means current vaccines must be updated and re-administered annually. 
This approach is time-consuming and expensive, and is often hindered by mismatches between circulating and 
vaccine strains. Strain mismatch can contribute to insufficient vaccine efficacy, which has ranged from just 10-
60% over the last decade. Furthermore, recent sporadic zoonotic outbreaks of novel highly pathogenic viruses 
from avian species, to which current vaccines provide no immunity, have been observed, with fatality rates 
around 40%. This raises serious concerns of a global pandemic with the potential to spread rapidly before a 
vaccine can be manufactured. Novel approaches to influenza vaccination are clearly needed in order to 
overcome these limitations with “universal” flu vaccines being the holy grail. We have stabilized recombinant 
influenza haemagglutinin (rHA) in its native, pre-fusion conformation by the addition of a novel “clamp” 
stabilization motif to enhance subunit vaccine potency and breadth of protection. Immunisation of mice with 
clamp-stabilized prefusion rHA elicited a potent neutralizing antibody response (~4-fold improvement over 
current vaccines). Most importantly, antibodies elicited upon immunisation with clamp-stabilised prefusion rHA 
showed an 80-fold increase in cross-reactivity to rHA derived from a divergent, highly pathogenic avian virus 
(H5N1) when compared to the current influenza vaccines. We have also shown that vaccination with clamp-
stabilisted rHA based on the H3 subtype (group 2) is capable of providing cross-protection to a challenge with a 
highly-divergent group 1 virus (H1N1). Ultimately, this approach could represent a potential universal influenza 
vaccine, providing enhanced cross-protection against both group 1 and 2 seasonal influenza virus strains while 





Figure 1 – Mice were vaccinated with rHA with (H3 Clamp) or 
without (H3 Sol) the molecular clamp trimerisation domain. A 
previously published influenza vaccine candidate utilizing the 
foldon trimerisation domain (H3 Foldon) was included as a 
direct comparison. Mice were challenged with a lethal dose of 
highly divergent H1N1pdm09 virus. Partial cross-protection 
was seen only in H3 clamp-vaccinated mice, but not with H3 
Sol or H3 Foldon groups. 
